8-K current report · filed Oct 28, 2026

GERON CORP (GERN) 8-K Current Report: October 28, 2026

Item 8.01Item EX-99.1GERN overview

Short answer

GERON CORP (GERN) filed an 8-K current report with the SEC on October 28, 2026 reporting Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1). Geron issued a Phase 3 IMpactMF trial update for imetelstat in JAK inhibitor relapsed/refractory myelofibrosis.

GERON CORP 8-K event analysis

AI summary of each reported item and its exhibits

Item 8.01 · Other Events

  • Geron issued a Phase 3 IMpactMF trial update for imetelstat in JAK inhibitor relapsed/refractory myelofibrosis
  • Clinical update may materially affect imetelstat approval prospects, development timelines, and Geron’s valuation
  • Full trial details and company commentary appear in Exhibit 99.1

Item EX-99.1 · Exhibit EX-99.1

  • Phase 3 IMpactMF discontinued after independent DMC judged overall-survival endpoint unlikely to be met
  • Trial enrolled 327 relapsed/refractory myelofibrosis patients after JAK-inhibitor treatment
  • No new safety signals, preserving imetelstat’s known safety profile but eliminating a major development opportunity
  • Near-term strategy shifts toward growing U.S. RYTELO demand and expanding access for eligible LR-MDS patients
  • Detailed efficacy and safety analyses pending, with findings planned for future scientific disclosure

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other GERON CORP 8-K filings

Get the next GERN 8-K as it lands

Follow GERN for push alerts, or ask the research agent what this filing means.